An analysis of the clinical application of paliperidone palmitate injection based on real-world.

ABSTRACT:

Objective

To analyze the clinical application, adherence and relapse of paliperidone palmitate (PP) injection.

Method

The information of patients treated with PP 1-month (PP1M), patients switching from PP1M to paliperidone palmitate 3-month (PP3M), and the relapse of patients after discharge from 1 January 2021 to 31 December 2023 was retrieved from the electronic medical record system. Descriptive statistics, two-tailed t-test and Chi-Squared test are used to process data.

Results

189 patients were administered with PP1M in this study accounted for 0.88% of all inpatients. 5 (9.09%) patients were switched from risperidone long-acting injection (RLAI) to PP1M. 45 (∼23.81%) patients were switched into PP3M. The patients without relapses were twice than relapsed

SUBMITTER: Liu R 

PROVIDER: S-EPMC11978662 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature